Novartis Scemblix®, with novel mechanism of action, sho

Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...

Related Keywords

Georgia , United States , East Hanover , Pennsylvania , Chicago , Illinois , Philadelphia , America , American , Jeff Legos , Jorgee Cortes , Sloan Simpson , Prnewswire Novartis , American Society Of Clinical Oncology , Twitter , European Hematology Association , Novartis , Exchange Commission , Global Head Of Oncology Hematology Development , Pfizer , Approval Program , Augusta University , Nj Novartis Pharmaceuticals Corporation , Georgia Cancer Center , Novartis Pharmaceuticals Corp , Clinical Oncology , Executive Vice President , Global Head , Hematology Development , Novartis Commitment , Prescribing Information , Pharmaceuticals Corporation , Randomized Study , Novartis Pharmaceuticals , Allosteric Inhibitor , Tyrosine Kinase Activity , Chronic Myeloid Leukemia , Reveals Significant , Durable Responses , Chronic Phase , Exhibits Safety , Phasei Study , Asciminib Plus Nilotinib , Therapy Using Asciminib Plus Imatinib , Previously Treated With , Adult Patients With Newly Diagnosed , More Tyrosine Kinase , Patients With , Treatment Optimization , Pediatric Patients With Chronic Myeloid Leukemia , Safety Results , Tyrosine Kinase Inhibitors , Novartis Us ,